Business
Mauna Kea Technologies Announces New Commercial Organization to Accelerate Growth Outside the United States
PARIS & BOSTON, February 04, 2026--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced key organizational changes to drive accelerated growth outside the United States. These moves build directly on the strong 2025 sales performance positioning the Company with two major growth drivers: pancreatic cysts and CellTolerance® (detection of food intoleran
About this update from Mauna Kea Technologies Sa Class O
[{"type":"text","content":"Building on Strong 2025 Momentum with Accelerated Sales Growth in Pancreatic Cysts & €1M Milestone for CellTolerance®","length":121,"tagName":"p","attribs":{}},{"type":"text","content":"Appointment of Benoit Chardon as Fractional Chief Commercial Officer to Lead Global Scale-Up of CellTolerance® Outside the United States","length":136,"tagName":"p","attribs":{}},{"type":"text","content":"Leveraging European Endoscopy (ESGE) Recommendation to Support Pancreatic Cyst Commercial Expansion","length":99,"tagName":"p","attribs":{}},{"type":"text","content":"PARIS & BOSTON, February 04, 2026--(BUSINESS WIRE)--Regulatory News:","length":72,"tagName":"p"},{"type":"text","content":"Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced key organizational changes to drive accelerated growth outside the United States. These moves build directly on the strong 2025 sales performance positioning the Company with two major growth drivers: pancreatic cysts and CellTolerance® (detection of food intolerances in patients suffering from IBS) scaling rapidly internationally.","length":516,"tagName":"p"},{"type":"text","content":"Following significant U.S. commercial restructuring in early 2025, which delivered sustained sales acceleration throughout the year, Mauna Kea is now sharpening its international strategy outside the United States. The organizational changes aim to capitalize on proven clinical momentum in pancreatic cyst characterization and unlock the high-potential market for CellTolerance® in Europe, the Middle East, Australia, and beyond.","length":430,"tagName":"p"},{"type":"text","content":"Benoit Chardon, who has served as Senior Strategic Advisor since 2024 and played a pivotal role in shaping CellTolerance®'s value proposition, branding, go-to-market strategy, and initial commercial rollout (Europe, Australia, and other regions), is appointed Fractional Chief Commercial Officer dedicated to CellTolerance®. With over 20 years of proven leadership in healthcare, weight loss, and medical aesthetics, Benoit Chardon has developed scalable playbooks for revenue development and value creation.","length":512,"tagName":"p"},{"type":"text","content":"Under his leadership, a dedicated, outsourced commercia...